In patients with metastatic NSCLC, would you consider atezolizumab after failure of nivolumab or pembrolizumab?   

 Is there any data to support this approach? If not, are there trials you are aware of looking at "rescuing" these patients with a different checkpoint inhibitor or combination of checkpoint inhibitors?